Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
A quick question. Who actually has control now at Hemogenyx? Since the Sandler’s collective shareholding fell below 20% and the continued dilution, they have operational control; but who are the significant institutions? If any?
HFH. It’s possible, but in the last five years only 2019 (Mon 29th) did they deviate from the 30th. It would be nice to think that the collective intellect of Dr Sandler and Professor Feldmann would report some tangible progress and a revised strategic outline based on their ‘unexpected’ cash inflow after year end.
Yes, anything in addition would be most welcome
If we look at previous years then a Final Result RNS for FY 2022 is a given for next Friday…either within, or after hours
Nature abhors a vacuum
Autocratic self-interest is not necessarily a bad thing.
HH. An excellent post. Our background and views appear to be uncannily similar, but I think any senior business manager would hold these rationales. I believe our due diligence and resolve will bear fruit. GLA
Use an ISA
Yeah, it’s from a Pfizer paper in 2020
Aussie reference is a publication date piggybacking on the Hemo/Lilly US patent application.
Mohammed wasn’t even born until 570AD!
Agreed Pumpky. 1.94 trades are buys
This is supposed to be a forum; actually behavior is like the colosseum
Hi Mickey. Appreciate the advice; I have every intention of doing so. The Guinness is in the fridge. It’s water off a duck’s back. You enjoy your beer too!
Oh by the way …121. It is your turn to jog on!
In October 2021 we secured an exclusive worldwide licence for all applications to intellectual property developed by Lilly related to the final form of the CDX bispecific antibody. With patent protection now secured (as described below), and following the valuable contributions made by Lilly, we believe that CDX should attract significant interest from financial or strategic partners in taking the asset forward to animal toxicology studies and ultimately clinical trials.
Following the year end, in January, the Company announced a partnership with Selexis SA (“Selexis”) to leverage Selexis’s SUREtechnology PlatformTM of protein expression technologies and modular workflows to advance the Company’s CDX bispecific antibody toward human trials. The service agreement will help the Company to reduce the time, effort, and costs associated with developing the cell line for the antibody for the treatment of AML.
JHFH. I am not sure why anyone would think that the FDA would put a hold on this. The company have been using a reputable compliance consultant to oversee the application. Lachmann employs former FDA staff to ensure that applications are not pushed back.
The good news guys, is that the teams at Hemo are focused on the task in hand.
It is a sequential process and Russian ruler still has some legs. Looking forward to more radio silence and a few update RNS on IND and CBR. Should be a news-rich April.
GLA
A Thursday RNS, this week
Pawnking1 or is it Nostradamus? All hail!
Pumpky. That Covid research evolved into the wider ranging CBR.